Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avant Immunotherapeutics, an integrated biopharmaceutical company, has announced that, pursuant to a previously announced shareholder vote, the company will change its name to Celldex Therapeutics, effective October 1, 2008.
Subscribe to our email newsletter
The board of directors also announced the appointment of Anthony Marucci, who has been serving as interim president and CEO since May 2008, as president and CEO of the company.
Avant Immunotherapeutics and Celldex Therapeutics completed a merger during the first quarter of 2008. The combined company’s internal pipeline is fueled by the creation of novel immunotherapy candidates based on Celldex’s precision targeted immunotherapy platform, said Avant.
Mr Marucci said: “This change reflects the company’s expertise and focus on developing therapeutic vaccines and antibodies, including the APC Targeted Technology platform which is a combination of both and is synonymous with the Celldex name.”
Charles Schaller, chairman of the board of Avant Immunotherapeutics, said: “Anthony has demonstrated strong leadership as Celldex has grown both operationally and scientifically. We are confident that under his guidance the company will continue to make rapid progress in the development of new immunotherapy-based treatments for cancer and other serious diseases. On behalf of the board, I am pleased to announce Anthony’s appointment and look forward to his continued contributions.”